Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028670 | 1.00 | HTR7 (0.40) | HTR7TRPM5GABRA1GABRG2GABRB3 | |
| SCHEMBL24958798 | 0.90 | HTR7 (0.42) | HTR7GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30028274 | 0.90 | HTR7 (0.42) | HTR7GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30029030 | 0.79 | TRPM5 (0.45) | HTR7TRPM5 | |
| SCHEMBL24958950 | 0.79 | TRPM5 (0.45) | HTR7TRPM5 | |
| SCHEMBL24956474 | 0.78 | HTR7 (0.40) | HTR7 | |
| SCHEMBL24959231 | 0.78 | HTR7 (0.40) | HTR7GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL24959138 | 0.78 | TRPM5 (0.37) | TRPM5 | |
| SCHEMBL24958966 | 0.77 | TRPM5 (0.36) | TRPM5 | |
| SCHEMBL30028557 | 0.77 | TRPM5 (0.36) | TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117295729-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | HTR7 280/4885TRPM5 1457/4885GABRA1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.